Global Pulmonary Drug Delivery Technology Market Size & Trends Report Segmented by Product (MDIs, DPIs, Nebulizers, Inhalers), Formulation (Liquid, Dry Powder, Aerosol), Application (COPD, Asthma, Cystic Fibrosis), End-user (Hospitals/Clinics, Homecare), & Regional Forecast to 2031

Pulmonary Drug Delivery Technologies are systems and devices designed to administer medications directly into the lungs to provide local or systemic therapeutic effects when inhaled. The devices used to deliver medications are typically metered dose inhalers (MDIs), dry-powder inhalers (DPIs), nebulizers, and soft mist inhalers (SMIs). These devices provide exact doses of medication in aerosol or powder form to be inhaled. This method of administration enables rapid drug absorption due to the lungs’ large surface area and extensive blood supply, thereby allowing a better response from the drug and reducing any potential side effects associated with systemic administration. Pulmonary drug delivery is commonly used for the treatment of several different respiratory diseases like asthma, COPD, cystic fibrosis, but there has been an increasing interest in using pulverized drug delivery to provide systemic therapeutic effects like vaccine, biologics, and peptide-based drugs among others.

Rising prevalence of respiratory diseases to propel market demand

A major contributor to the market for pulmonary drug delivery technology market is the increasing prevalence of respiratory conditions. Chronic respiratory issues like asthma, COPD, and pulmonary fibrosis are increasing around the world due to several factors such as an aging population, increasing tobacco use, long-term exposure to air pollution, workplace hazards, and urban population growth. According to WHO, COPD is the fourth leading cause of death worldwide, causing 3.5 million deaths in 2021, approximately 5% of all global deaths; while Asthma affected an estimated 262 million people in 2019 and caused 455000 deaths. A significant contributor to the development of chronic lung diseases is the increase in air pollution, especially in developing countries, where exposure to ambient particulate matter, environmental contaminants from industrial emissions and motor vehicles directly affects lung health and increases the incidence of chronic lung diseases. Tobacco use, both directly from smoking and indirectly from exposure to passive smoke, continues to be a leading cause of death from chronic lung disease, substantially contributing to the increasing number of patients with chronic lung disease in need of long-term inhalation therapy.

The increasing number of elderly patients with chronic lung diseases also contributes to the demand for inhalation therapeutics since the elderly have less reserve lung capacity, have decreased immune systems, and have had lifetime accumulative exposure to environmental toxins. Both demographics are driving the increase in the number of patients requiring ongoing and consistent respiratory care, which is driving market growth for inhalation-based medication delivery systems. Compared to systemically delivered oral or parenteral medications, medications delivered via the lungs have the benefits of fast onset of action, higher concentration of drug at the desired site of action, and fewer negative side effects than medications administered with other routes of administration. These advantages make inhalation therapy the preferred treatment approach for most respiratory diseases, ensuring sustained demand for inhalers and nebulizers.

Moreover, the rise of respiratory illnesses and new viral diseases has created a greater understanding of lung health and increased the demand for effective therapies for the lungs. People with asthma and/or COPD often need drugs for life via inhalers; as a result, there is continual demand for inhaler devices and the medications used in them. Furthermore, doctors are increasingly suggesting newer advanced delivery methods such as dry powder inhalers (DPI) or mesh nebulizers to help drive increased compliance and outcomes.

As healthcare access continues to improve in developing countries, with the increase in diagnoses as a result, there are now many more people who were previously not treated. Additionally, the goal of healthcare systems is to treat diseases early on to help reduce hospital admissions and complications, thus increasing the reliance upon home-based pulmonary drug delivery systems. With the continued growth in the burden of respiratory diseases, we can expect an increasing demand for effective, easy-to-use, targeted delivery systems for pulmonary drug delivery technology, thereby supporting ongoing growth within the market.

To learn more about this report, download the PDF brochure

Clinical benefits of targeted lung delivery are driving the market growth

The growing market for pulmonary drug delivery technology is largely based on the therapeutic advantages of delivering medication to the lungs. Pulmonary drug delivery allows drug delivery to the area of the disease while oral or injectable methods deliver medication into the entire body; therefore, pulmonary drug delivery is often the fastest and most efficient method to administer therapeutic agents into the lung. Localizing the delivery of drug therapy leads to faster drug responses, which is important in the management of acute respiratory symptoms like bronchospasm in patients with asthma and difficulty breathing in patients with COPD. Rapid symptom relief improves patient comfort and reduces the risk of disease exacerbations and emergency interventions.

Another advantage of pulmonary delivery technology is the increase in drug bioavailability at the target site. Drugs administered through inhalation deliver higher concentrations of drugs to the lung tissue than any other method of drug delivery, therefore allowing the clinician to use lower doses to administer effective doses of medication. The decreased dose of medication allows for the likelihood of side effects from systemic administration to be significantly reduced. Reducing drug exposure to the whole body is particularly important for patients with chronic respiratory disease requiring daily maintenance medications for extended periods of time.

Targeted lung delivery also enhances treatment efficiency for both local and systemic therapies. The lung offers a large total surface area, thin walls between blood vessels and airway epithelium, allowing many types of drugs to be absorbed directly into the bloodstream at a rapid rate when they enter the lungs through the airways. This makes pulmonary delivery suitable not only for respiratory conditions but also for systemic therapies such as inhaled insulin, vaccines, and biologics under development. The potential for addressing new areas of care using pulmonary drug delivery technologies has begun to expand beyond therapies for the treatment of respiratory conditions.   

Targeted delivery also enhances patient adherence and treatment outcomes. Inhalation devices are usually minimally invasive, simple to operate and can be used in a person's own home, which makes them more acceptable to patients than injections. When a person's drug is delivered consistently and accurately via inhalation, it may help to reduce hospitalization rates, slow disease progression, and decrease total healthcare costs. Inhalation treatments are increasingly favored by healthcare providers due to their ability to provide superior symptom control with minimal complications. As clinical studies show that inhalation delivery is more effective, safer, and easier than traditional routes of drug administration, the demand for advanced pulmonary drug delivery technologies is expected to increase steadily, driving sustained market growth.

Growth strategies adopted by players to establish their foothold in the market

Players operating in this market are adopting various growth strategies such as new product launches and approvals, acquisitions, expansions, and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

• In March 2026, Aerogen opened its India headquarters in New Delhi to expand access to advanced vibrating mesh nebulizer technology and strengthen respiratory care infrastructure. The expansion supports growing demand for pulmonary drug delivery solutions in India and reinforces Aerogen’s commitment to innovation, partnerships, and market growth across the APAC region
• In February 2026, Zydus Lifesciences launched PEPAIR, India’s first affordable OPEP device to support mucus clearance and improve breathing in patients with COPD, asthma, and bronchiectasis. The handheld, drug-free device strengthens pulmonary care and expands access to respiratory support solutions amid the rising burden of chronic respiratory diseases in India
• In December 2025, Amneal Pharmaceuticals, Inc. received USFDA approval for its albuterol sulfate inhalation aerosol, the generic equivalent of ProAir HFA, expanding its respiratory inhalation portfolio. This follows its earlier approval for generic beclomethasone inhalation aerosol, strengthening the company’s position in complex pulmonary drug delivery and respiratory therapeutics
• In October 2025, Merck & Co., Inc. acquired Verona Pharma plc for $10 billion, making it a wholly owned subsidiary. The acquisition adds Ohtuvayre, a first-in-class inhaled COPD therapy, strengthening Merck’s cardio-pulmonary and pulmonary drug delivery portfolio
• In February 2025, MicroBase Technology partnered with Taiwan Biotech to develop a nebulized pulmonary drug delivery platform targeting elderly and pediatric respiratory patients. The collaboration integrates inhalation medications with sustained-release nebulization technology and aims to expand advanced respiratory therapies across Taiwan and Southeast Asia
• In January 2025, Molex (parent company of Phillips Medisize) completed the acquisition of Vectura Group Ltd. to expand Phillips Medisize’s inhalation drug delivery capabilities. The deal strengthens expertise in dry powder inhalers, metered dose inhalers, and nebulizers, enhancing end-to-end pulmonary drug delivery development and manufacturing services
• In September 2024, Aptar Pharma entered an exclusive collaboration with Pulmotree to develop and promote the Kolibri non-propellant liquid inhaler platform. The partnership strengthens advanced pulmonary drug delivery by enabling breath-triggered, propellant-free inhalation systems with improved lung deposition and digital connectivity features

To learn more about this report, download the PDF brochure

Product Type Segment Outlook

By product type MDIs hold the largest share of the pulmonary drug delivery market because of their long-established clinical use, widespread availability, lower cost, and their extensive successful utilization for the treatment of both asthma and COPD. The characteristics of MDIs such as ease of transport, familiarity among patients and physicians, and availability of both branded products and generics, keep MDIs in the lead position. Connected inhalers are the fastest-growing segment of the inhaled medication market. There is an uptick in the integration of digital health technologies that include adherence monitoring, remote patient engagement, and clinical research focused on patient usage data for treatment protocols. As a result, smart inhalers can provide real-time monitoring of patient usage, help patients stay on their intended treatment regiment, and enhance their ability to receive personalized healthcare, consequently, this segment is rapidly becoming preferred by healthcare systems as they move toward a data-driven strategy and implement digital solutions to support the management of respiratory diseases.

Regional Outlook: North America expected to hold a major share in the pulmonary drug delivery technology market

North America holds the largest share of pulmonary drug delivery technology market, due to high prevalence of asthma and COPD, availability of advanced healthcare infrastructure, high number of major pharmaceutical and device manufacturers located in this region and early adoption of innovative inhalation technologies such as smart inhalers and mesh nebulizers. Other factors contributing to the large share of North America in this market include supportive reimbursement policies and substantial investment in R&D. Asia Pacific is the fastest-growing region, with higher levels of air pollution, larger patient population and increased healthcare spending as well as greater availability of respiratory care and an increase in pharmaceutical manufacturing. Other contributing factors to regional market expansion include greater levels of public awareness, healthcare programs funded, and more widespread acceptance of portable or home-based inhalation devices.

Competitive Landscape Analysis

The global pulmonary drug delivery technology market is marked by the presence of established and emerging market players such as AstraZeneca (UK); GSK (UK); Novartis AG (Switzerland); Boehringer Ingelheim (Germany); Teva Pharmaceutical Industries Ltd. (Israel); 3M (US); Koninklijke Philips N.V. (The Netherlands); OMRON Corporation (Japan); Johnson & Johnson (US); and Cipla Limited (India); among others. Some of the key strategies adopted by market players include new product launches and approvals, acquisitions, expansions, and strategic partnerships, agreements, and collaborations.

Get a sample report for competitive landscape analysis

Report Scope

Global Pulmonary Drug Delivery Technology Market Segmentation

This report by Medi-Tech Insights provides the size of the global pulmonary drug delivery technology market at the regional- and country-level from 2024 to 2031. The report further segments the market based on product type, formulation type, application, and end user.

Market Size & Forecast (2024-2031), By Product Type, USD Billion

• Metered Dose Inhalers (MDIs)
• Dry Powder Inhalers (DPIs)
• Nebulizers
  • Jet Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers
• Soft Mist Inhalers
• Smart/Connected Inhalers

Market Size & Forecast (2024-2031), By Formulation Type, USD Billion

• Liquid Formulations
• Dry Powder Formulations
• Aerosol Formulations

Market Size & Forecast (2024-2031), By Application, USD Billion

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Pulmonary Arterial Hypertension
• Allergic Rhinitis
• Other Applications

Market Size & Forecast (2024-2031), By End User, USD Billion

• Hospitals & Clinics
• Ambulatory Surgical Centers (ASCs)
• Home Care Settings
• Other End Users

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Reports

Respiratory Care Devices Market (2026-2031) Size, Share, Analysis By Product (Respiratory Care Monitoring Devices, Diagnostics Respiratory Care Devices, Consumables and Accessories), Disease (Sleep Apnea, Asthma, Infectious Diseases), Region and Segment Forecast

Global Cough Assisted Devices Market Size & Trends Report Segmented by Product Type (Automatic, Manual), Choice of Delivery (Mouthpiece, Face Mask, Adapter), End-user (Hospitals, Home-care Settings) Industry Analysis & Regional Forecast to 2030

Global Neonatal Intensive Care Respiratory Devices Market Size & Trends Report Segmented by Device Type (Nebulizers, Inhalers, Ventilators, Apnea Monitors), End-user (Hospitals, Specialty Clinics, Nursing Homes) & Regional Forecast to 2030